DermaTend Firm Faces Re-Labeling To Keep Lotions On Market
This article was originally published in The Tan Sheet
Executive Summary
Solace International’s recall announcement says “DermaTend is not FDA approved,” and “Using these DermaTend products instead of seeking medical attention could result in delayed diagnosis of conditions such as cancer.”
You may also be interested in...
In Brief
NAD refers Solace to FTC; ERSP chastises TriVita for testimonials; Perrigo gains second China formula distributor; CHPA comments on lobbying regulations; Acetaminophen linked to asthma in children; CSPI pushes for St. John’s wort warning
FDA Combines Supplement GMP Recordkeeping, Testing Waiver Estimates
On CRN Challenge, Nexus Formulas Gets Lesson On Supporting Ad Claims For Supplements
So full of errors were the firm's online ads for its Plavinol supplement, the National Advertising Division noted support for some claims contained "many of the same flaws" as others. The prevalence of problems prompted NAD to go outside its "scope of review" and note unclear instructions on Plavinol labels.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: